Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.16
IART's Cash-to-Debt is ranked lower than
91% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. IART: 0.16 )
Ranked among companies with meaningful Cash-to-Debt only.
IART' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.62 Max: No Debt
Current: 0.16
Equity-to-Asset 0.42
IART's Equity-to-Asset is ranked lower than
72% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. IART: 0.42 )
Ranked among companies with meaningful Equity-to-Asset only.
IART' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.56 Max: 0.97
Current: 0.42
0.29
0.97
Interest Coverage 4.20
IART's Interest Coverage is ranked lower than
87% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. IART: 4.20 )
Ranked among companies with meaningful Interest Coverage only.
IART' s Interest Coverage Range Over the Past 10 Years
Min: 1.58  Med: 3.35 Max: 5.38
Current: 4.2
1.58
5.38
Piotroski F-Score: 5
Altman Z-Score: 2.90
Beneish M-Score: -2.61
WACC vs ROIC
5.66%
6.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 10.18
IART's Operating Margin % is ranked higher than
73% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. IART: 10.18 )
Ranked among companies with meaningful Operating Margin % only.
IART' s Operating Margin % Range Over the Past 10 Years
Min: 5.08  Med: 8.95 Max: 14.33
Current: 10.18
5.08
14.33
Net Margin % 6.66
IART's Net Margin % is ranked higher than
69% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. IART: 6.66 )
Ranked among companies with meaningful Net Margin % only.
IART' s Net Margin % Range Over the Past 10 Years
Min: -3.02  Med: 4.62 Max: 8.97
Current: 6.66
-3.02
8.97
ROE % 8.26
IART's ROE % is ranked higher than
68% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. IART: 8.26 )
Ranked among companies with meaningful ROE % only.
IART' s ROE % Range Over the Past 10 Years
Min: -3.56  Med: 8.46 Max: 13.9
Current: 8.26
-3.56
13.9
ROA % 3.62
IART's ROA % is ranked higher than
65% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. IART: 3.62 )
Ranked among companies with meaningful ROA % only.
IART' s ROA % Range Over the Past 10 Years
Min: -1.79  Med: 3.29 Max: 6.71
Current: 3.62
-1.79
6.71
ROC (Joel Greenblatt) % 21.52
IART's ROC (Joel Greenblatt) % is ranked higher than
73% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. IART: 21.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IART' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 8.48  Med: 17.62 Max: 32.36
Current: 21.52
8.48
32.36
3-Year Revenue Growth Rate 1.20
IART's 3-Year Revenue Growth Rate is ranked lower than
63% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. IART: 1.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IART' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -5.3  Med: 15.8 Max: 55
Current: 1.2
-5.3
55
3-Year EBITDA Growth Rate 25.50
IART's 3-Year EBITDA Growth Rate is ranked higher than
76% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. IART: 25.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IART' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -38  Med: 10.35 Max: 35.1
Current: 25.5
-38
35.1
3-Year EPS without NRI Growth Rate 35.20
IART's 3-Year EPS without NRI Growth Rate is ranked higher than
84% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. IART: 35.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IART' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.2  Med: -3.05 Max: 35.2
Current: 35.2
-48.2
35.2
GuruFocus has detected 4 Warning Signs with Integra Lifesciences Holdings Corp $IART.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IART's 30-Y Financials

Financials (Next Earnings Date: 2017-07-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

IART Guru Trades in Q2 2016

RS Investment Management 709,503 sh (New)
Jim Simons 102,530 sh (+207.62%)
David Dreman Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 503,365 sh (-7.62%)
Richard Snow 174,405 sh (-19.68%)
Steven Cohen 258,400 sh (-40.65%)
» More
Q3 2016

IART Guru Trades in Q3 2016

Paul Tudor Jones 8,005 sh (New)
Ken Fisher 526,405 sh (+4.58%)
Steven Cohen 100,000 sh (unchged)
Steven Cohen Sold Out
Richard Snow 146,930 sh (-15.75%)
Jim Simons 19,030 sh (-81.44%)
» More
Q4 2016

IART Guru Trades in Q4 2016

Joel Greenblatt 11,704 sh (New)
Steven Cohen 100,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 521,330 sh (-0.96%)
Richard Snow 66,070 sh (-55.03%)
» More
Q1 2017

IART Guru Trades in Q1 2017

Paul Tudor Jones 14,629 sh (New)
Jim Simons 173,660 sh (New)
Joel Greenblatt 34,783 sh (+48.59%)
Richard Snow Sold Out
Ken Fisher 1,031,310 sh (-1.09%)
» More
» Details

Insider Trades

Latest Guru Trades with IART

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:NUVA, OTCPK:EKTAY, OTCPK:GGNDF, OTCPK:FSPKF, NYSE:GMED, NAS:MASI, OTCPK:AMBFF, NYSE:PEN, NAS:WMGI, NAS:LIVN, NAS:ZLTQ, NYSE:NVRO, OTCPK:NHNKY, NAS:INGN, OTCPK:IOBCF, NAS:CYNO, NAS:MDXG, NAS:CNMD, NAS:ABMD, OTCPK:NMRD » details
Traded in other countries:IL3.Germany,
Headquarter Location:USA
Integra Lifesciences Holdings Corp is engaged in development, manufacturing, and marketing of product lines from its technology for applications ranging from burn and deep tissue wounds to repair of dura mater in the brain to repair of nerve and tendon.

Integra Lifesciences Holdings Corp was incorporated in Delaware in 1989. The Company develops, manufactures and market cost-effective surgical implants and medical instruments. Its products are used mainly in neurosurgery, extremity reconstruction, orthopedics and general surgery. The Company sells its products directly through various sales forces and through various distribution channels. The Company currently manufactures and sells its products in five reportable business segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. Its U.S. Neurosurgery sales organization sells a full line of products specifically for neurosurgery and neuro critical care. The Company has products for each step of a cranial procedure and the care of the patient after surgery. Its key products include dural repair products, tissue ablation equipment, intracranial monitoring equipment, cranial stabilization equipment, and cerebral spinal fluid management devices. It sells equipment used in the neurosurgery operating room and neurosurgery intensive care unit. It sells its products through directly employed sales representatives. U.S. Extremities; the Company define extremity reconstruction to mean the repair of soft tissue and the orthopedic reconstruction of bone in the foot, ankle and leg below the knee, and the hand, wrist, elbow and shoulder. Its key products include bone and joint fixation devices, implants and instruments for osteoarthritis, rheumatoid arthritis, wrist and shoulder arthroplasty, carpal tunnel syndrome, and cubital tunnel syndrome. Other key products include its regenerative medicine devices for the treatment of acute and chronic wounds, peripheral nerve repair and protection and tendon repair, and bone graft substitutes. The Company sells its products through a direct sales organization and through specialty distributors focused on their respective surgical disciplines. Its U.S. Instruments business portfolio includes over 60,000 instrument patterns and surgical products, including hospitals, surgery centers, and physician, dental and veterinary offices. In addition to selling hand-held instruments, it sells surgical headlight systems and table-mounted retractors. Its brands includes Jarit, Miltex, Padgett, Ruggles, Luxtec and Omni-Tract. The Company's U.S. Spine and Other segment offers comprehensive spinal fusion technologies that surgeons use along the full length of the spine, as well as differentiated offering of related orthobiologics. This segment also includes private-label sales of a broad set of its regenerative medicine technologies. The International segment sells similar products, but they are managed through Europe, Middle East and Africa, Latin/South America, Asia-Pacific, Australia, New Zealand and Canada. The Company's trademarks include AccuDrain, Accell, Accell Evo3, Advansys, Atoll , Ascension, Bold, Budde, Buzz , Camino, CRW, Coral, CUSA, Daytona, DenLite, Dur

Top Ranked Articles about Integra Lifesciences Holdings Corp

Integra LifeSciences to Present at Healthcare Conferences in June 2017
Integra LifeSciences Announces Agreement with aap to Distribute LOQTEQ® Distal Radius System
Integra LifeSciences launches SurgiMend® MP Collagen Matrix for Hernia Repair
Integra LifeSciences to Present at Healthcare Conferences in May 2017
Integra LifeSciences to Host Its First Quarter 2017 Earnings Results Conference Call on April 26, 2017
Integra LifeSciences Announces Expansion of Credit Facility to include new $700 million term loan
Integra LifeSciences Announces Commercial Expansion of the Cadence® Total Ankle System

PLAINSBORO, N.J., March 28, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced full commercial availability of its Cadence® Total Ankle System, a new ankle prosthesis developed in partnership with four world leading foot and ankle surgeons – Dr. Tim Daniels (University of Toronto), Dr. David Pedowitz (Rothman Institute, Philadelphia, Pa.), Dr. Selene Parekh (Duke University, Durham, N.C.) and Dr. Christopher Hyer (Orthopedic Foot & Ankle Center, Westerville, Ohio).
More than 200 Cadence total ankle procedures have been successfully performed in seven countries, since initial clinical use more than a year ago.  During this period, instrumentation updates and enhanced surgeon training were introduced, designed to further improve quality, patient safety, and procedural efficiency of the system. Integra completed corrective actions required to close an FDA recall related to the clarification of the system surgical technique, which addressed a small percentage of intra-operative posterior tibial fractures occurring due to technique error.  The recall required no return of product, and since the implementation of the clarified surgical technique, no subsequent posterior tibial fractures have occurred in more than 100 procedures. The Cadence system has garnered positive feedback among its users for advancements in implant and instrument design, along with a streamlined surgical technique.  Cadence incorporates several features to accommodate various patient anatomies, reduce potential clinical complications, and address common challenges associated with ankle arthroplasty procedure.  Key implant features include: Side-specific, anatomical tibial components, designed to avoid fibular impingement.Side-specific, anatomical talar components, designed to minimize resected talar bone and to preserve vascularity in the ankle. Bearing insert components manufactured from a highly crosslinked ultra-high molecular weight polyethylene (HXL UHMWPE) for improved wear characteristics, and patent pending-biased sagittal profile options to address patients with subluxed talar anatomy. “I’ve implanted over 50 Cadence Total Ankle prostheses.  I am very impressed with the versatility, reliability, reproducibility, and short-term outcomes of this implant,” said Dr. Tim Daniels. “The streamlined and reliable operative instruments and techniques of this procedure, combined with an anatomical design, offer significant advantages over other ankle systems on the market today.” The Cadence Total Ankle System was previously available in a limited market release. The Cadence system is now fully available in the United States, Canada, and select European countries.  Integra plans to initiate several global post-market clinical studies with the Cadence system to further support product efficacy. About Integra
Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care.  Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies.  For more information, please visit www.integralife.com. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Company

Investors
Angela Steinway
609-936-2268
[email protected]

Michael Beaulieu
609-750-2827
[email protected]

Media
Laurene Isip
609-750-7984
[email protected]

Read more...
Integra LifeSciences Introduces Next Generation CUSA® Clarity Ultrasonic Tissue Ablation System
PLAINSBORO, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a global leader in medical technology, announces the launch of its new CUSA® Clarity ultrasonic tissue ablation platform designed to deliver an innovative, integrated system for enhanced performance and long-lasting surgeon comfort in neurosurgical cases.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8b5375f4-19a1-46ed-9d75-880d2ddd6006Integra’s CUSA® Clarity was engineered to maximize surgical performance for surgeons, staff and patients through a system that provides power, precision and comfort for complex neurosurgery. The unique CUSA® Clarity system is the only ultrasonic tissue ablation system that combines a tough tissue tip, continuous tissue contact, a precision and ergonomic handpiece, and adaptive power all in one system.  These four integrated components provide a greater than 50 percent increase in fibrous tissue removal rate over the CUSA® Excel system.The next generation CUSA® Clarity also features an improved handpiece design with a focus on sustained comfort and precision as well as a sleek new console design with an intuitive touchscreen and CUSA Quick Connect™ cartridge and tubing set to streamline operating room setup and workflow. The system is a scalable platform to support future enhancements.“This latest innovation in tissue ablation is a result of Integra’s focus on designing and developing an advanced system that meets the surgeons’ needs for enhanced surgical performance, especially for longer and tougher cases like fibrous tissue removal,” says Dan Reuvers, president of the Specialty Surgical Solutions division for Integra. “We’re delighted to bring this new system to a demanding surgical environment that enhances patient care.”The CUSA® Clarity was developed with extensive feedback from over 150 touchpoints worldwide. CUSA® Clarity is currently available for sale in the U.S. and select EU countries (contact your representative for more information). For U.S. customers, a 98.5% uptime guarantee is available with the addition of Integra’s IntegraLink™ Protection Plus program. CUSA® Clarity was cleared by the U.S. Food and Drug Administration and has obtained CE Mark approval. For more information and further indications for use, visit our website for U.S. customers.About Integra
Integra LifeSciences Holdings Corporation, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.
CONTACT: Integra LifeSciences Holdings Corporation

Investors
Angela Steinway
609-936-2268
[email protected]  

Michael Beaulieu
609-750-2827
[email protected]  

Media
Laurene Isip
609-750-7984
[email protected]

Read more...
Integra LifeSciences Launches Press-Fit Reverse Shoulder for Fracture for the Titan™ Modular Shoulder System

PLAINSBORO, N.J., March 15, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ:IART), a leading global medical technology company, announced the launch of the Titan™ Press-Fit Reverse Shoulder for Fracture. The use of the reverse shoulder to treat humeral fractures has increased in recent years. However, heat from cement used to secure the prosthesis can hinder healing of the bone, which negatively impacts patient outcomes.1 The Titan reverse is one of the few prostheses that does not require cement, due to its unique two-piece stem that achieves a direct implant-to-bone press-fit fixation below the fracture line in the humeral canal. Stems that fixate in the humeral canal have a strong clinical heritage, with published literature showing comparable or better functional results in fracture scenarios compared to published studies of other stem designs.2 Matt Ramsey, MD, of the Rothman Institute said, “This product has revolutionized my treatment of proximal humeral fractures. The Titan Press-Fit Reverse allows me to reliably obtain a solid fit in the canal without having to wait for the cement to dry, and the ability to adjust height and version independent of the stem means no fiddling with a jig or making sacrifices on the fit.” The Titan Press-Fit Reverse for Fracture was developed in conjunction with Matthew Ramsey, MD; William Geissler, MD; Sanford Kunkel, MD; Jean-Marc Glasson, MD; Phillip Duke, MBBS, FRACS, FA(ORTH)A; and Mark Ross, MBBS, FRACS, FA(ORTH)A. “The Titan Press-Fit Reverse for Fracture is a cornerstone of our shoulder portfolio.  At Integra, we’re committed to creating products that enhance patient care and enrich the surgeon experience.  Our shoulder franchise is poised to redefine expectations in shoulder arthroplasty with this and other products we have in the pipeline,” said Bob Davis, president of Integra’s Orthopedics & Tissue Technologies division. About Integra
Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care.  Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies.  For more information, please visit www.integralife.com. For additional information on the release of the Titan™ Modular Shoulder System Press-Fit Reverse for Fracture, please contact [email protected]. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.  1 Formaini, NT, Everding, NG, Levy, JC, Rosas, S. Tuberosity healing after reverse shoulder arthroplasty for acute proximal humerus fractures: the “black and tan” technique. J Shoulder Elbow Surg 2015 Nov;24(11):e299-306. doi: 10.1016/j.jse.2015.04.014. Epub 2015 Jul 2.
2 Ross, M, Hope, B, Stokes, A, Peters, SE, McLeod, I, Duke, PFR. Reverse Shoulder Arthroplasty for the treatment of three-part and four-part proximal humeral fractures in the elderly. J Shoulder Elbow Surg 2015 Feb;24(2):215-22. doi: 10.1016/j.jse.2014.05.022. Epub 2014 Aug 29.
CONTACT: Integra LifeSciences Holdings Company

Investors
Angela Steinway                                             
609-936-2268                                                                   
[email protected]

Michael Beaulieu
609-750-2827
[email protected]

Media
Laurene Isip
609-750-7984
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 58.39
IART's PE Ratio is ranked lower than
70% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 27.53 vs. IART: 58.39 )
Ranked among companies with meaningful PE Ratio only.
IART' s PE Ratio Range Over the Past 10 Years
Min: 15.26  Med: 33.27 Max: 6446
Current: 58.39
15.26
6446
Forward PE Ratio 25.71
IART's Forward PE Ratio is ranked lower than
52% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 21.79 vs. IART: 25.71 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 58.39
IART's PE Ratio without NRI is ranked lower than
71% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. IART: 58.39 )
Ranked among companies with meaningful PE Ratio without NRI only.
IART' s PE Ratio without NRI Range Over the Past 10 Years
Min: 15.16  Med: 33.78 Max: 391.18
Current: 58.39
15.16
391.18
Price-to-Owner-Earnings 41.18
IART's Price-to-Owner-Earnings is ranked lower than
59% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 32.96 vs. IART: 41.18 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
IART' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.25  Med: 28.44 Max: 1344.69
Current: 41.18
8.25
1344.69
PB Ratio 4.33
IART's PB Ratio is ranked lower than
58% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. IART: 4.33 )
Ranked among companies with meaningful PB Ratio only.
IART' s PB Ratio Range Over the Past 10 Years
Min: 1.21  Med: 2.35 Max: 5.46
Current: 4.33
1.21
5.46
PS Ratio 3.85
IART's PS Ratio is ranked lower than
53% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. IART: 3.85 )
Ranked among companies with meaningful PS Ratio only.
IART' s PS Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.79 Max: 3.9
Current: 3.85
0.79
3.9
Price-to-Free-Cash-Flow 52.24
IART's Price-to-Free-Cash-Flow is ranked lower than
72% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. IART: 52.24 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
IART' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.16  Med: 24.84 Max: 122.19
Current: 52.24
6.16
122.19
Price-to-Operating-Cash-Flow 32.48
IART's Price-to-Operating-Cash-Flow is ranked lower than
67% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. IART: 32.48 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IART' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.38  Med: 18.53 Max: 32.88
Current: 32.48
5.38
32.88
EV-to-EBIT 42.29
IART's EV-to-EBIT is ranked lower than
67% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. IART: 42.29 )
Ranked among companies with meaningful EV-to-EBIT only.
IART' s EV-to-EBIT Range Over the Past 10 Years
Min: -149.8  Med: 22.5 Max: 49.9
Current: 42.29
-149.8
49.9
EV-to-EBITDA 24.76
IART's EV-to-EBITDA is ranked lower than
54% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. IART: 24.76 )
Ranked among companies with meaningful EV-to-EBITDA only.
IART' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.1  Med: 15.3 Max: 41.5
Current: 24.76
8.1
41.5
PEG Ratio 13.90
IART's PEG Ratio is ranked lower than
84% of the 83 Companies
in the Global Medical Devices industry.

( Industry Median: 2.52 vs. IART: 13.90 )
Ranked among companies with meaningful PEG Ratio only.
IART' s PEG Ratio Range Over the Past 10 Years
Min: 0.03  Med: 1.52 Max: 2173.22
Current: 13.9
0.03
2173.22
Shiller PE Ratio 86.71
IART's Shiller PE Ratio is ranked lower than
70% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 49.41 vs. IART: 86.71 )
Ranked among companies with meaningful Shiller PE Ratio only.
IART' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.3  Med: 39.02 Max: 294.33
Current: 86.71
17.3
294.33
Current Ratio 3.02
IART's Current Ratio is ranked higher than
73% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. IART: 3.02 )
Ranked among companies with meaningful Current Ratio only.
IART' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 4.25 Max: 20.74
Current: 3.02
0.81
20.74
Quick Ratio 1.75
IART's Quick Ratio is ranked higher than
59% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. IART: 1.75 )
Ranked among companies with meaningful Quick Ratio only.
IART' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 2.67 Max: 19.26
Current: 1.75
0.46
19.26
Days Inventory 232.83
IART's Days Inventory is ranked lower than
75% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. IART: 232.83 )
Ranked among companies with meaningful Days Inventory only.
IART' s Days Inventory Range Over the Past 10 Years
Min: 194.11  Med: 211.58 Max: 247.25
Current: 232.83
194.11
247.25
Days Sales Outstanding 56.96
IART's Days Sales Outstanding is ranked higher than
70% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. IART: 56.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
IART' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.48  Med: 54.95 Max: 68.65
Current: 56.96
50.48
68.65
Days Payable 47.43
IART's Days Payable is ranked lower than
78% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. IART: 47.43 )
Ranked among companies with meaningful Days Payable only.
IART' s Days Payable Range Over the Past 10 Years
Min: 30.38  Med: 37.24 Max: 66.27
Current: 47.43
30.38
66.27

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.20
IART's 3-Year Average Share Buyback Ratio is ranked lower than
54% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. IART: -5.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IART' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.8  Med: -4 Max: 3.1
Current: -5.2
-18.8
3.1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.53
IART's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
65% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. IART: 3.53 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
IART' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.62 Max: 9.6
Current: 3.53
0.62
9.6
Price-to-Median-PS-Value 2.15
IART's Price-to-Median-PS-Value is ranked lower than
86% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. IART: 2.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IART' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.78 Max: 10.73
Current: 2.15
0.54
10.73
Price-to-Peter-Lynch-Fair-Value 9.45
IART's Price-to-Peter-Lynch-Fair-Value is ranked lower than
96% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 1.61 vs. IART: 9.45 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
IART' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.35  Med: 1.29 Max: 8.35
Current: 9.45
0.35
8.35
Earnings Yield (Greenblatt) % 2.36
IART's Earnings Yield (Greenblatt) % is ranked higher than
60% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. IART: 2.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IART' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2  Med: 4.4 Max: 8.4
Current: 2.36
2
8.4
Forward Rate of Return (Yacktman) % 7.28
IART's Forward Rate of Return (Yacktman) % is ranked lower than
58% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.85 vs. IART: 7.28 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
IART' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8.7  Med: 21.25 Max: 965.8
Current: 7.28
-8.7
965.8

More Statistics

Revenue (TTM) (Mil) $1,014
EPS (TTM) $ 0.84
Beta0.69
Short Percentage of Float13.09%
52-Week Range $36.13 - 50.05
Shares Outstanding (Mil)75.62

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,131 1,226 1,308
EPS ($) 1.92 2.21 2.49
EPS without NRI ($) 1.92 2.21 2.49
EPS Growth Rate
(Future 3Y To 5Y Estimate)
13.00%
Dividends per Share ($)
» More Articles for IART

Headlines

Articles On GuruFocus.com
Integra LifeSciences to Present at Healthcare Conferences in June 2017 May 24 2017 
Integra LifeSciences Announces Agreement with aap to Distribute LOQTEQ® Distal Radius System May 23 2017 
Integra LifeSciences launches SurgiMend® MP Collagen Matrix for Hernia Repair May 12 2017 
Integra LifeSciences to Present at Healthcare Conferences in May 2017 May 03 2017 
Integra LifeSciences to Host Its First Quarter 2017 Earnings Results Conference Call on April 26, 2 Apr 12 2017 
Integra LifeSciences Announces Expansion of Credit Facility to include new $700 million term loan Apr 04 2017 
Integra LifeSciences Announces Commercial Expansion of the Cadence® Total Ankle System Mar 28 2017 
Integra LifeSciences Introduces Next Generation CUSA® Clarity Ultrasonic Tissue Ablation System Mar 16 2017 
Integra LifeSciences Launches Press-Fit Reverse Shoulder for Fracture for the Titan™ Modular Sh Mar 15 2017 
SeaSpine: A Pure-Play Medical Spinoff Jul 22 2015 

More From Other Websites
Integra LifeSciences to Present at Healthcare Conferences in June 2017 May 24 2017
Integra LifeSciences to Offer aap's LOQTEQ System in the US May 24 2017
Integra LifeSciences Announces Agreement with aap to Distribute LOQTEQ® Distal Radius System May 23 2017
Integra Lifesciences Hits 52-Week High on Product Launches May 22 2017
Integra LifeSciences Announces the European Launch of Integra® Dermal Regeneration Template Single... May 17 2017
Integra LifeSciences launches SurgiMend® MP Collagen Matrix for Hernia Repair May 12 2017
ETFs with exposure to Integra LifeSciences Holdings Corp. : May 11, 2017 May 11 2017
Integra LifeSciences to Present at Healthcare Conferences in May 2017 May 03 2017
Integra LifeSciences Holdings Corp. :IART-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28,... Apr 28 2017
Edited Transcript of IART earnings conference call or presentation 26-Apr-17 12:30pm GMT Apr 27 2017
Integra LifeSciences (IART) Misses Q1 Earnings, Retains View Apr 27 2017
Integra misses 1Q profit forecasts Apr 26 2017
Integra LifeSciences Reports First Quarter 2017 Financial Results Apr 26 2017
Integra LifeSciences Holdings Corp. – Value Analysis (NASDAQ:IART) : April 24, 2017 Apr 24 2017
Integra LifeSciences Holdings Corp. breached its 50 day moving average in a Bullish Manner : IART-US... Apr 21 2017
Integra LifeSciences' Stock Split: Why It Accomplished Nothing Apr 15 2017
Integra LifeSciences (IART) Q1 Earnings: A Beat in Store? Apr 13 2017
Integra LifeSciences to Host Its First Quarter 2017 Earnings Results Conference Call on April 26,... Apr 12 2017
Integra LifeSciences Announces Expansion of Credit Facility to include new $700 million term loan Apr 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)